novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

14 Março 2018

Todos os estudos aqui apresentados podem ser consultados na íntegra no site do American College of Cardiology

http://www.acc.org/education-and-meetings/image-and-slide-gallery

Tags:
ACC 2018

Five-Year Outcomes From the All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial in Patients with Severe Aortic Valve Stenosis

14 Março 2018
0

OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance in Non-Ischemic Heart Failure (IMAGE-HF project 1B)

14 Março 2018
0

-->